NYXOAH SA
NYXHNASDAQTrading Snapshot
- Day Range
- $0.88 – $0.92
- 52-Week Range
- $0.80 – $5.92
- Volume (shares)
- 122,098.99
- Avg Volume (shares)
- —
- Shares Outstanding
- 101.8M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $10M
- Last Q Revenue
- $8M
- P/E Ratio
- -0.4
- P/S Ratio
- 3.6x
- EPS (TTM)
- $-1.73
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +8.3%
NYXOAH SA
NYXH
StockOtter · stockotter.spaceAbout NYXOAH SA
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026
Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026 Mont-Saint-Guibert, Belgium – October 26, 2026, 10:05 pm CET / 5:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”
Here's Why Nyxoah (NYXH) Could be Great Choice for a Bottom Fisher
Nyxoah (NYXH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in rev
Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026 U.S. net revenue grows 29% sequentially, driving third quarter global prel
Contrasting Nephros (NASDAQ:NEPH) & Nyxoah (NASDAQ:NYXH)
Nyxoah (NASDAQ: NYXH - Get Free Report) and Nephros (NASDAQ: NEPH - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength o
Nyxoah: Label Expansion Set To Unlock A Monopoly In A Billion Dollar Market.
Nyxoah is entering its first growth stage, targeting the OSA device market with the Genio implant, and is currently undervalued relative to growth prospects. Genio could secure a monopoly on 30% of the OSA market by 2027
Nyxoah Appoints Liam Kelly as Chief Executive Officer
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Appoints Liam Kelly as Chief Executive Officer Further strengthening the Company's strategic U.S. presence and focus Mont-Saint-Guibert, Belgium – September 28, 2026, 10:30